ABBV vs JNJ: Dividend Comparison
Dividend data as of
AbbVie Inc. (ABBV) and Johnson & Johnson (JNJ) are both in the Health Care sector, making them natural rivals for dividend investors. ABBV edges ahead on yield at 2.92% versus JNJ's 2.16%. For dividend growth, ABBV leads with a 5-year CAGR of 13.9% versus JNJ's 5.2%. Both stocks carry a "Safe" dividend safety rating. JNJ is a Dividend King with 63 years of consecutive increases.
Verdict
Yield Analysis
ABBV yields 0.76% more than JNJ. In dollar terms, ABBV pays $6.65/share vs JNJ's $5.14/share annually.
Dividend Growth
ABBV: Dividend growth is accelerating — the 3-year CAGR of 21.6% exceeds the 5-year rate of 13.9% and the 10-year rate of 16.1%.
JNJ: Dividend growth is slowing — the 3-year CAGR of 4.6% trails the 5-year rate of 5.2% and the 10-year rate of 5.6%.
Dividend Safety
ABBV: The payout ratio of 3% is well within sustainable levels, leaving room for future increases. Earnings cover the dividend 0.4x.
JNJ: The payout ratio of 47% is well within sustainable levels, leaving room for future increases. Earnings cover the dividend 2.1x.
Estimated Annual Dividend Income
Based on current dividend yields. Actual income may vary.
What does $10,000 buy in ABBV vs JNJ today?
At $231.90 per share, $10,000 buys about 43.1 shares of AbbVie Inc. (ABBV). Each share pays $6.65 per year in dividends, so the position starts out generating roughly $287 per year — about $24 a month.
At $243.53 per share, $10,000 buys about 41.1 shares of Johnson & Johnson (JNJ). Each share pays $5.14 per year in dividends, so the position starts out generating roughly $211 per year — about $18 a month.
ABBV is the larger income stream from day one: $76 per year more on the same $10,000 invested.
What could $10,000 of ABBV or JNJ income look like in 10 years?
AbbVie Inc. (ABBV) has raised its dividend about 13.9% a year over the past five years. If that pace held, the $292 per year that $10,000 generates today at the current 2.92% yield would reach $1,071 per year by 2036 — a 10.7% yield on the original cost.
Johnson & Johnson (JNJ) has raised its dividend about 5.2% a year over the past five years. If that pace held, the $216 per year that $10,000 generates today at the current 2.16% yield would reach $359 per year by 2036 — a 3.6% yield on the original cost.
On those trailing rates, ABBV pays more in 2036: $1,071 versus $359 per year. The projection assumes each five-year growth rate persists and no dividends are reinvested — real payouts will differ.
When would JNJ's dividend growth overtake ABBV's higher yield?
It doesn't, on the trailing numbers. AbbVie Inc. (ABBV) yields more today (2.92% vs 2.16%) and has also grown its dividend at least as fast (13.9% vs 5.2% a year over five years). Unless JNJ accelerates its raises or ABBV stumbles, JNJ never closes the income gap — ABBV wins on both current income and growth.
Can ABBV and JNJ afford their dividends?
AbbVie Inc. (ABBV) earns $2.37 per share against $6.65 paid out in dividends — 0.4x coverage (a 3% payout ratio).
Johnson & Johnson (JNJ) earns $11.03 per share against $5.14 paid out in dividends — 2.1x coverage (a 47% payout ratio).
JNJ's wider coverage leaves more cushion if earnings dip. As a rule of thumb, coverage below about 1.5x (a payout ratio above ~65%) is where a dividend starts to look stretched — worth watching for ABBV if earnings weaken.
Which fits an early-retirement income portfolio better, ABBV or JNJ?
For income you need right now, AbbVie Inc. (ABBV) leads: $100,000 invested today pays about $243 a month at the current 2.92% yield, versus $180 a month from Johnson & Johnson (JNJ) at 2.16%.
ABBV also leads on dividend growth (13.9% vs 5.2% a year over five years), so the trailing numbers favor it on both fronts.
On consistency: JNJ has raised its dividend 63 consecutive years.
Many income investors simply hold both — the mix pairs current yield with growth and spreads single-name risk. Whichever way you lean, dividends are never guaranteed; recheck the payout each quarter rather than setting and forgetting.
$10,000 with DRIP: projected annual income
If each holding keeps raising its dividend at its real 5-year rate and every payment is reinvested, a $10,000 position pays $1,428/yr in ABBV vs $445/yr in JNJ by year 10.
Assumes dividends are reinvested at the current yield and grow at each holding's trailing 5-year dividend CAGR. A projection, not a prediction — no price appreciation modeled.
Track ABBV and JNJ in your portfolio
See your real income from both — forward projections, yield on cost, and dividend safety signals. Sync your brokerage free for 30 days, or track holdings manually on the free plan.
Frequently Asked Questions
Related Resources
Individual Stock Analysis
Dividend Tools
Track Your Dividends
More Comparisons
This tool is for educational and informational purposes only and does not constitute investment, financial, tax, or legal advice. Consult a licensed professional before making investment decisions.
Past performance does not guarantee future results. All projections are hypothetical estimates based on user-provided inputs and may differ materially from actual outcomes.
By using this tool you agree to our Terms of Service and Privacy Policy.